CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of canc ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Effective anti-tumor immunity is not only defined by which immune cells are present in a tumor, but also by how they are organized in space. Across cancer ...

The tumor microenvironment (TME) represents a complex and dynamic network that plays a critical role in the pathogenesis and progression of cancer. This intricate landscape encompasses a diverse array ...

Immunotherapy has revolutionized cancer treatment, yet response rates remain highly variable across tumor types and individual patients. Increasing evidence ...

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

Roles of CAFs in shaping the lymphatic metastatic landscape. Schematic illustration of various mechanisms through which CAF subsets shape the lymphatic metastatic landscape, including the physical ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...